For the November journal club we will discuss a phase II trial of chemoradiation de-escalation for oropharyngeal cancer. Human papillomavirus (HPV)-related oropharyngeal cancers have a favorable prognosis – can we get the same cancer control and less side effects with less treatment?
We have changed the format to a single day. Please join us with Dr. Bhishamjit Chera of UNC Lineberger Cancer Center on Sunday November 22nd 6 AM to 8 PM Central Standard Time for global discussion. At 8-9 PM CST, we have a live chat as usual.
Thanks to the editors at IJROBP for making the article available as open access for the journal club. You can get it here.
We will discuss the following questions:
1A. What is the current standard for chemoradiation in oropharyngeal cancer?
1B. What are the main treatment toxicities that may be lessened with de-escalation?
2. What was the phase II study design and rationale?
3. What were the results, and how to they compare to current standards?
4. What issues need to be addressed in a phase III trial to confirm de-escalation is safe?